For the year ending 2025-12-31, XNCR had $13,100K increase in cash & cash equivalents over the period. -$138,267K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total | 125,576 |
| External research and development expense-Xm Ab819ENPP3XCD3 | 23,119 |
| External research and development expense-Xm Ab657CD19XCD3 | 13,767 |
| External research and development expense-Xm Ab942Xtend TL1A | 13,419 |
| External research and development expense-Xm Ab541CLDN6XCD3 | 12,742 |
| External research and development expense-Xm Ab412TL1AXIL23p19 | 8,064 |
| External research and development expense-Plamotamab CD20XCD3 | 7,229 |
| External research and development expense-Xm Ab808B7H3XCD28 | 5,888 |
| External research and development expense-Other Programs Including Research And Early Stage | 18,229 |
| External research and development expense-Wind Down Costs Of Terminated Programs | 17,224 |
| Internal research and development expenses | 94,783 |
| Research and development stock based compensation | 24,970 |
| General and administrative | 63,644 |
| Other income (expense), net | 87,869 |
| Income tax expense | 2,504 |
| Net loss including noncontrolling interest | -92,137 |
| Depreciation and amortization | 10,512 |
| Accretion of discount on marketable debt securities, net | 3,481 |
| Stock-based compensation | 43,227 |
| Gain on sale of marketable securities, net | 14,388 |
| Change in fair value of marketable equity securities | 87,126 |
| Asset impairment charges | 9,169 |
| Non-cash royalty revenue related to the sale of future royalties | 80,266 |
| Non-cash interest expense on liabilities related to the sale of future royalties | 31,921 |
| Equity received in connection with license agreement | 0 |
| Abandonment of capitalized intangibles | 0 |
| Loss on disposal of assets | 0 |
| Accounts receivable | -28,734 |
| Interest receivable from marketable debt securities | -2,622 |
| Prepaid expenses and other assets | -9,441 |
| Accounts payable | -3,953 |
| Accrued expenses | 13,796 |
| Income taxes | 3,589 |
| Operating lease, net | 400 |
| Deferred revenue | 0 |
| Other assets and liabilities, net | 7,177 |
| Net cash used in operating activities | -135,117 |
| Purchase of marketable debt securities | 298,895 |
| Purchase of property and equipment | 3,150 |
| Purchase of patents | 0 |
| Proceeds from sales of marketable equity securities | 36,941 |
| Proceeds from sales and maturities of marketable debt securities | 405,089 |
| Proceeds from sale of property and equipment | 0 |
| Net cash provided by (used in) investing activities | 139,985 |
| Proceeds from the exercises of stock options | 8,667 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 1,290 |
| Proceeds from issuance of common stock and pre-funded warrants | 0 |
| Common stock and pre-funded warrants issuance costs | 0 |
| Proceeds from the sale of future royalties | 0 |
| Proceeds from noncontrolling interest | 0 |
| Cash paid to acquire noncontrolling interest | 1,725 |
| Net cash provided by financing activities | 8,232 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 13,100 |
| Cash, cash equivalents, and restricted cash, beginning of period | 41,262 |
| Cash, cash equivalents, and restricted cash, end of period | 54,362 |
Xencor Inc (XNCR)
Xencor Inc (XNCR)